Cover Image
市場調查報告書

全身性紅斑性狼瘡 (SLE) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析

Systematic lupus erythematosus: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365197
出版日期 內容資訊 英文 190 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身性紅斑性狼瘡 (SLE) :流行病學、患者為基礎的市場預測,治療流程,及上市藥、開發平台藥物分析 Systematic lupus erythematosus: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年04月01日 內容資訊: 英文 190 Pages
簡介

本報告以全身性紅斑性狼瘡 (SLE)的已上市及臨床實驗中 (開發平台上)的治療藥為焦點,提供今後10年的市場預測,Benlysta的核准治療流程及臨床實驗設計的影響,今後10年的市場成長的促進要素,最受新產品銷售影響的病患群,在SLE可見的後期階段臨床實驗失敗的要素,為了在該市場競爭新藥表示的必要臨床特性等相關分析。

預測:全身性紅斑性狼瘡 (SLE)

  • 摘要整理
  • 市場概要、趨勢
  • 市場定義、調查手法
  • anifrolumab
  • Benlysta SLE (belimumab)
  • blisibimod
  • 1次調查手法

流行病學:全身性紅斑性狼瘡 (SLE)

  • 摘要整理
  • 來源、手法
  • 預測
  • 流行病學者的見解
  • 優勢和弱點

上市藥:全身性紅斑性狼瘡 (SLE)

  • 摘要整理
  • 產品概要
  • 1次調查手法
  • 產品簡介:Benlysta
  • 產品簡介:非標籤藥物,CellCept
  • 產品簡介:非標籤藥物,Rituxan

開發平台:全身性紅斑性狼瘡 (SLE)

  • 摘要整理
  • 臨床實驗平台概要
  • 比較儀治療
  • 臨床實驗設計
  • 疾病治療的未來
  • 最近開發中止的藥物
  • 1次調查手法
  • 目標產品簡介
  • 產品簡介 (後期階段) :Lupuzor
  • 產品簡介 (後期階段) :anifrolumab
  • 產品簡介 (後期階段) :atacicept
  • 產品簡介 (後期階段) :blisibimod

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5364

Datamonitor Healthcare forecasts a shift in the systemic lupus erythematosus (SLE) market over the next 10 years, as new product approvals drive a movement from traditional off-label treatment to prescribing of approved therapies.

This report addresses the following questions:

  • How has the approval of Benlysta impacted the treatment algorithm and clinical trial design?
  • What will drive growth in the SLE market over the next 10 years, and which patient groups will be most impacted by new product launches?
  • What factors have led to the late-phase clinical trial failures that continue to be seen in SLE?
  • Which clinical attributes will a new drug need to demonstrate in order to compete in this market?

TABLE OF CONTENTS

FORECAST: SYSTEMIC LUPUS ERYTHEMATOSUS

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Market Definition and Methodology
  • 4. anifrolumab
  • 5. Benlysta SLE (belimumab)
  • 6. blisibimod
  • 7. Primary Research Methodology

EPIDEMIOLOGY: SYSTEMIC LUPUS ERYTHEMATOSUS

  • 8. Executive Summary
  • 9. Sources and Methodology
  • 10. Forecast
  • 11. Epidemiologist Insight
  • 12. Strengths and Limitations

MARKETED DRUGS: SYSTEMIC LUPUS ERYTHEMATOSUS

  • 13. Executive Summary
  • 14. Product Overview
  • 15. Primary Research Methodology
  • 16. Product profile: Benlysta
  • 17. Product profile: Off-label: CellCept
  • 18. Product profile: Off-label: Rituxan

PIPELINE: SYSTEMIC LUPUS ERYTHEMATOSUS

  • 19. Executive Summary
  • 20. Clinical Pipeline Overview
  • 21. Comparator Therapy
  • 22. Clinical Trial Design
  • 23. The Future of Disease Treatment
  • 24. Recently Discontinued Drugs
  • 25. Primary Research Methodology
  • 26. Product profile (late stage): Lupuzor
  • 27. Product profile (late stage): anifrolumab
  • 28. Product profile (late stage): atacicept
  • 29. Product profile (late stage): blisibimod
Back to Top